PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 10893741

[Executive function and its disorders].

D A Pineda
View original source ↗Export metadata ↓

Abstract

INTRODUCTION: Executive function is a set of cognitive operations, which are sustained by the complex activities of the frontal lobe systems. Executive function is responsible for programming, establishing goals, classifying, executing, controlling, changing, monitoring and confronting all the mental activities. OBJECTIVE: To review and to actualize neuropsychological literature about executive function, its development, its structure, its theoretical model, its alterations in different neurological and neuropsychological disorders, and its clinical qualitative and quantitative assessments. CONCLUSION: Executive function is a multidimensional construct of the cognition, which is structured and modified through the development during childhood, and which is altered during different neurological and neuropsychological disorders, and which could be evaluated in a qualitative or quantitative approaches.

Explore related subjects

Cognition DisordersHumansNeuropsychological TestsPrefrontal CortexEnglish AbstractJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

D A Pineda. [Executive function and its disorders].. https://pubmed.ncbi.nlm.nih.gov/10893741/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2002

Elucidating continuities and discontinuities between schizotypy and schizophrenia in the nervous system.

Genetic epidemiological studies indicate that schizophrenia is a complexly inherited disorder, whereby multiple genes, additively and in interaction with environmental factors, contribute to increasing risk for phenotypic expression. Linkage studies have identified a number of chromosomal regions as likely to harbor susceptibility genes for schizophrenia, but the linked regions span relatively large chromosomal segments in each case. These efforts have been hindered in part by a lack of means to detect nonpenetrant carriers of predisposing genes and in part by uncertainties concerning the nature of the nongenetic factors involved and their mechanisms of action in relation to genetic factors. Our strategy has focused on elucidating changes in central nervous system structure, physiology, and function that mark an inherited genotype for schizophrenia and on identifying specific environmental and etiological contributors and their modes of action in relation to genetic factors. The research reviewed in this paper, making use of family and twin designs, suggests that certain neural system deficits in schizophrenia (e.g., prefrontal cortex, working memory) are reflective of an inherited diathesis to the disorder, while others (e.g., temporal cortex, episodic memory) result from the interacting influences of genetic factors and particular types of biologically disruptive environmental events (e.g., fetal hypoxia). These findings help to reveal continuities and discontinuities in the neural disturbances characteristic of the schizophrenia genotype and phenotype and encourage the use of quantitative neural trait measures in the search for schizophrenia susceptibility genes.

Cognition Disorders↗
PubMed2002

An integration of schizophrenia with schizotypy: identification of schizotaxia and implications for research on treatment and prevention.

The liability to schizophrenia (schizotaxia) is associated with deficits in a variety of domains, including negative symptoms and neuropsychological deficits, even in the absence of psychosis or pre-psychotic prodromal symptoms. Conceptually, this view of schizotaxia is similar to negative schizotypy (i.e., schizotypal personality disorder minus the positive symptoms). It is broader than DSM-IV schizotypal personality disorder (SPD), however, in that more relatives of patients with schizophrenia show core symptoms of schizotaxia than meet the diagnostic criteria for SPD. Three lines of evidence support the validity of schizotaxia. First, evidence of concurrent validation was obtained by showing that schizotaxic subjects were more impaired than non-schizotaxic subjects on a variety of independent clinical scales. Second, schizotaxic subjects showed higher levels of negative symptoms on the Structured Interview for Schizotypy than non-schizotaxic subjects, but did not differ on positive symptoms. Third, subjects who met predetermined criteria for schizotaxia (i.e., negative symptoms and neuropsychological deficits) showed positive effects following treatment with low doses of risperidone (0.25-2.0 mg). Thus, clinical deficits in schizotaxia may be identifiable, and to a significant extent, reversible. Implications for the conception of schizotypy and the prevention of schizophrenia will be discussed.

Cognition Disorders↗